Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average Rating of “Hold” from Brokerages

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has received a consensus recommendation of “Hold” from the six ratings firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $19.33.

A number of equities research analysts have recently issued reports on ENTA shares. StockNews.com lowered shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, April 6th. JPMorgan Chase & Co. dropped their target price on shares of Enanta Pharmaceuticals from $12.00 to $11.00 and set an “underweight” rating for the company in a report on Thursday, February 8th.

Enanta Pharmaceuticals Price Performance

ENTA opened at $13.32 on Friday. The firm has a fifty day moving average price of $14.82 and a 200 day moving average price of $11.74. Enanta Pharmaceuticals has a 1 year low of $8.08 and a 1 year high of $37.75. The stock has a market cap of $281.80 million, a P/E ratio of -2.03 and a beta of 0.47.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($1.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.40). The company had revenue of $18.00 million for the quarter, compared to analyst estimates of $22.74 million. Enanta Pharmaceuticals had a negative return on equity of 60.38% and a negative net margin of 187.77%. Equities analysts expect that Enanta Pharmaceuticals will post -4.9 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. State of Tennessee Treasury Department raised its holdings in Enanta Pharmaceuticals by 3.0% in the fourth quarter. State of Tennessee Treasury Department now owns 13,142 shares of the biotechnology company’s stock valued at $611,000 after acquiring an additional 386 shares in the last quarter. Yousif Capital Management LLC increased its stake in Enanta Pharmaceuticals by 2.8% in the first quarter. Yousif Capital Management LLC now owns 16,477 shares of the biotechnology company’s stock valued at $1,173,000 after purchasing an additional 445 shares during the last quarter. Two Sigma Investments LP increased its stake in Enanta Pharmaceuticals by 4.4% in the third quarter. Two Sigma Investments LP now owns 14,192 shares of the biotechnology company’s stock valued at $736,000 after purchasing an additional 601 shares during the last quarter. Captrust Financial Advisors increased its stake in Enanta Pharmaceuticals by 343.8% in the first quarter. Captrust Financial Advisors now owns 852 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 660 shares during the last quarter. Finally, State of Wisconsin Investment Board increased its stake in Enanta Pharmaceuticals by 3.2% in the second quarter. State of Wisconsin Investment Board now owns 21,984 shares of the biotechnology company’s stock valued at $470,000 after purchasing an additional 676 shares during the last quarter. Hedge funds and other institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.